Drugs / GD2 CAR-T immunotherapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04406610 | Sep 2015 → Aug 2016 | brain glioma | Fuda Cancer Hospital, Guangzhou | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GD2 CAR-T immunotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04406610 ↗ |
| Modality | Cell therapy | “Antigen-specific T cell therapy” NCT04406610 ↗ |
| Route | Intravenous | “Treated by GD2 CAR-T therapy intravenously” NCT04406610 ↗ |